drugset

drugset / Trial / NCT03452345

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

NCT03452345 ↗

Phase 3 Completed 180 enrolled Medy-Tox

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

Timeline

Start: 2018-04-09
Primary completion: 2019-01-31
Completion: 2019-04-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meditoxin	Protein / enzyme biologic	—	—

Indications